Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risankizumab - AbbVie/Boehringer Ingelheim

Drug Profile

Risankizumab - AbbVie/Boehringer Ingelheim

Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZI

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Registered Erythrodermic psoriasis; Generalised pustular psoriasis
  • Preregistration Ulcerative colitis
  • Phase III Palmoplantar pustulosis
  • Phase II Atopic dermatitis; Hidradenitis suppurativa
  • No development reported Unspecified
  • Discontinued Ankylosing spondylitis; Asthma

Most Recent Events

  • 16 Jan 2024 Phase-III clinical trials in Psoriatic arthritis (In children, In adolescents, Treatment-experienced) in USA (SC) (NCT06100744) (EudraCT20235060263600)
  • 29 Nov 2023 AbbVie completes an open-label extension phase III trial in plaque psoriasis in USA, Canada, Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Japan, South Korea, Mexico, Poland, Portugal, Spain, Sweden and Taiwan (NCT03047395) (EudraCT2016-003046-87)
  • 20 Nov 2023 AbbVie initiates a phase I bioavailability trial (In volunteers) in US (IV, infusion) (NCT06054425),
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top